Aptevo officer converts 638 RSUs into common shares

Aptevo Therapeutics Inc. reported that officer SoYoung Kwon (SVP, GC, BD & Corp Affairs) exercised 638 Restricted Stock Units into 638 shares of common stock on August 6, 2026.

Accepted by SEC EDGAR 08/10/2026 - 09:36 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Aptevo Therapeutics Inc. reported that officer SoYoung Kwon (SVP, GC, BD & Corp Affairs) exercised 638 Restricted Stock Units into 638 shares of common stock on August 6, 2026. The RSUs converted to common stock on a one-for-one basis, leaving 0 RSUs from this grant and resulting in 638 common shares held directly.

Insider Trade Summary

638 shares exercised/converted

Exercise 2 txns

Insider Kwon SoYoung

Role SVP, GC, BD & Corp Affairs

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit F1, F2	638	$0.00	$0.00
Exercise	Common Stock F1	638	--	--

Holdings After Transaction: Restricted Stock Unit — 0 units (Direct); Common Stock — 638 shares (Direct)

Footnotes (2)

1. F1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
2. F2. On August 6, 2025, the reporting person was granted 11,500 (638 post-split) RSUs, vesting on the first anniversary of the date of grant.

Key Figures

RSUs exercised: 638 RSUs Common shares received: 638 shares RSUs remaining from this grant: 0 RSUs +2 more

5 metrics

RSUs exercised 638 RSUs Restricted Stock Units converted to common stock on August 6, 2026

Common shares received 638 shares Shares of Aptevo common stock received upon RSU conversion

RSUs remaining from this grant 0 RSUs Total RSUs following the reported derivative transaction

Common shares held after transaction 638 shares Direct ownership position after the August 6, 2026 transaction

Original RSU grant size 11,500 RSUs RSUs granted on August 6, 2025 (638 post-split) vesting after one year

Key Terms

Restricted Stock Unit, one-for-one basis, post-split

3 terms

Restricted Stock Unit financial

"The security title reported is "Restricted Stock Unit"."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

one-for-one basis financial

"RSUs convert into common stock on a one-for-one basis."

post-split financial

"The reporting person was granted 11,500 (638 post-split) RSUs."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Aptevo Therapeutics (APVO) report for SoYoung Kwon?

Aptevo reported that SoYoung Kwon exercised 638 Restricted Stock Units into 638 shares of common stock on August 6, 2026, as part of previously granted equity compensation.

How many Aptevo Therapeutics (APVO) RSUs did SoYoung Kwon convert and what did she receive?

She converted 638 RSUs, which turned into 638 shares of Aptevo common stock on a one-for-one basis, reflecting the standard RSU-to-share conversion ratio described in the filing footnotes.

What are SoYoung Kwon’s Aptevo (APVO) holdings after the August 6, 2026 transaction?

Following the transaction, SoYoung Kwon directly holds 638 shares of Aptevo common stock. The specific RSU grant involved in this transaction shows 0 RSUs remaining after conversion.

What was the origin of the 638 RSUs reported for Aptevo Therapeutics (APVO)?

According to the footnotes, on August 6, 2025, SoYoung Kwon was granted 11,500 RSUs (638 post-split), which were scheduled to vest on the first anniversary of the grant date and then convert into common stock.

Was the Aptevo (APVO) Form 4 transaction under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmed, and the footnotes do not reference a trading plan, so the reported RSU conversion does not indicate 10b5-1 plan status.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kwon SoYoung

(Last) (First) (Middle)

2401 4TH AVENUE

SUITE 1050

(Street)

SEATTLE WASHINGTON 98121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GC, BD & Corp Affairs

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/06/2026		M		638	A	(1)	638	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	08/06/2026		M			638	(2)	(2)	Common Stock	638	$0	0	D

Explanation of Responses:

1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.

2. On August 6, 2025, the reporting person was granted 11,500 (638 post-split) RSUs, vesting on the first anniversary of the date of grant.

	/s/ SoYoung Kwon, Attorney-in-Fact	08/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)